1) Partnered with Eisai for lecanemab for treatment of Alzheimer’s disease. Eisai entered partnership with Biogen regarding BAN2401 (lecanemab) in 2014
2 AbbVie in-licensed BAN0805 in late 2018 and has developed the antibody with the designation ABBV-0805. On April 20, 2022, AbbVie informed BioArctic that it had taken a strategic business decision to terminate the collaboration regarding BioArctic’s alpha-synuclein portfolio. BioArctic are currently working with AbbVie to transfer the projects back with the aim of finding a new partner
3) Mild cognitive impairment due to Alzheimer’s disease and mild Alzheimer’s disease
4) Normal cognitive function with intermediate or elevated levels of amyloid in the brain
5) Dementia and cognitive impairment associated with Down’s syndrome and with traumatic brain injury
BioArctic’s portfolio has projects in several focus areas and in various phases from discovery through clinical development. Project portfolio as of June 30, 2022.
